Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23568514 | 0.79 | NPC1 (0.47) | NPC1HRH3 | |
| SCHEMBL13401 | 0.78 | CYP1A2 (0.42) | NPC1HRH3CYP1A2CHRM5ADRA2C | |
| SCHEMBL24608216 | 0.74 | HSD11B1 (0.43) | NPC1HRH3CHRM5 | |
| SCHEMBL18082747 | 0.74 | CYP1A2 (0.39) | NPC1HRH3CYP1A2CHRM5ADRA2C | |
| SCHEMBL11532640 | 0.72 | NPC1 (0.58) | NPC1HRH3CYP1A2PSMB1PSMB5 | |
| SCHEMBL134912 | 0.72 | HRH3 (0.69) | HRH3CYP1A2ALDH1A1POLBMAPT | |
| SCHEMBL4786815 | 0.72 | HRH3 (0.69) | HRH3CYP1A2ALDH1A1POLBMAPT | |
| SCHEMBL12826 | 0.72 | HRH3 (0.69) | HRH3CYP1A2ALDH1A1POLBMAPT | |
| SCHEMBL23828671 | 0.72 | HRH3 (0.69) | HRH3CYP1A2ALDH1A1POLBMAPT | |
| SCHEMBL5466977 | 0.72 | HRH3 (0.69) | HRH3CYP1A2ALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | NPC1 2550/4885HRH3 3443/4885CYP1A2 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.